definiens: mean s, with respect to a given Collaboration Druggable / LDD Target, any drug Development program that ( a ) has, as one of its ultimate goals, the Devel opment of one ( 1 ) or more compounds or products that are Directed to such Druggable / LDD Ta rget using the Synthetic Lethal relationship betwee n such Druggable / LDD Target and any Collaboration Campaign Lesion(s ) to define the patient population for suc h compound or product ; and ( b ) is initiated or continued by [COMPANY] or any of i ts Affiliates or Sublicensees ( i ) under this Agreement at any time following [COMPANY] ’s exercise of i ts Option pursuant to Section 2.7.2 with respect to the Collaboration Campaign under which Repare has ident ified a Synthetic Lethal relationship between such Collaboration Druggable / LDD Target and the Collabor ation Campaign Lesion(s ) that are the subject of su ch Collaboration Campaign or ( ii ) whether or not under this Agreement, at any time prior to the expiratio n of the Economics Bearing Term for such Collaboration Drugg able / LDD Target, including any such program that BM S or any of its Affiliates ( A ) has in - licensed or oth erwise acquired from any Third Party prior to the - 2 - Table of Contents Effective Date or ( B ) in - licenses or otherwise acqu ires during the Economics Bearing Term for such Collaboration Druggable / LDD Target by exercising an option right held by [COMPANY] or any of its Affiliates on or before the Effective Date ( each such program descri bed in ( A ) or ( B ), a ) ; but excluding any Acquired D ruggable / LDD Target Third Party Development Program